Eli Lilly and (NYSE:LLY) Research Coverage Started at SVB Leerink

Stock analysts at SVB Leerink initiated coverage on shares of Eli Lilly and (NYSE:LLYGet Rating) in a note issued to investors on Monday, The Fly reports. The brokerage set an “outperform” rating on the stock.

LLY has been the subject of several other research reports. Wells Fargo & Company boosted their target price on Eli Lilly and from $280.00 to $305.00 in a research note on Friday, April 29th. Mizuho boosted their price objective on Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. Morgan Stanley boosted their price objective on Eli Lilly and from $364.00 to $369.00 in a research note on Friday, April 29th. Bank of America boosted their price objective on Eli Lilly and from $300.00 to $315.00 in a research note on Thursday, March 17th. Finally, The Goldman Sachs Group boosted their target price on Eli Lilly and from $234.00 to $264.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $302.56.

Shares of LLY opened at $298.85 on Monday. The stock has a 50-day simple moving average of $292.36 and a 200-day simple moving average of $267.87. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. The stock has a market capitalization of $283.96 billion, a PE ratio of 44.27, a PEG ratio of 2.27 and a beta of 0.40. Eli Lilly and has a 1 year low of $195.50 and a 1 year high of $314.00.

Eli Lilly and (NYSE:LLYGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The company reported $2.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.30. The business had revenue of $7.81 billion during the quarter, compared to analysts’ expectations of $7.29 billion. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.87 EPS. Analysts predict that Eli Lilly and will post 8.25 EPS for the current year.

In other Eli Lilly and news, CAO Donald A. Zakrowski sold 1,660 shares of the company’s stock in a transaction dated Friday, February 25th. The stock was sold at an average price of $243.84, for a total transaction of $404,774.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 139,045 shares of the stock in a transaction dated Friday, April 8th. The shares were sold at an average price of $310.79, for a total value of $43,213,795.55. Following the completion of the sale, the insider now owns 105,573,810 shares of the company’s stock, valued at approximately $32,811,284,409.90. The disclosure for this sale can be found here. Insiders have sold 1,169,012 shares of company stock worth $332,350,306 over the last quarter. 0.12% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Eli Lilly and by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock valued at $20,183,695,000 after purchasing an additional 1,219,424 shares in the last quarter. State Street Corp lifted its holdings in Eli Lilly and by 2.5% during the 4th quarter. State Street Corp now owns 33,929,864 shares of the company’s stock worth $9,372,107,000 after buying an additional 813,983 shares during the last quarter. Capital World Investors lifted its holdings in Eli Lilly and by 17.0% during the 1st quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock worth $6,402,838,000 after buying an additional 3,242,548 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Eli Lilly and by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 14,731,168 shares of the company’s stock worth $4,059,130,000 after buying an additional 409,009 shares during the last quarter. Finally, Capital International Investors lifted its holdings in Eli Lilly and by 30.5% during the 1st quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock worth $2,532,024,000 after buying an additional 2,063,557 shares during the last quarter. Hedge funds and other institutional investors own 82.75% of the company’s stock.

Eli Lilly and Company Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

The Fly logo

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.